The Signature Program: Bringing the Protocol to the Patient

Clin Pharmacol Ther. 2015 Aug;98(2):124-6. doi: 10.1002/cpt.126. Epub 2015 May 11.

Abstract

Early-phase clinical development in oncology has evolved dramatically with the deciphering of the human genome in 2004. Genomic analysis and the tools identifying genetically disrupted pathways within a patient's tumor have been a driving force for personalized medicine and for the development of highly targeted novel therapies. Tumors are often genetically heterogeneous, with multiple concurrent genetic abnormalities. On the other hand, tumors arising from different tissues may share identical molecular drivers.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Algorithms
  • Biomarkers, Tumor / genetics*
  • Critical Pathways
  • Gene Expression Profiling*
  • Genetic Predisposition to Disease
  • Genetic Testing* / methods
  • Humans
  • Medical Oncology / methods*
  • Neoplasms / genetics*
  • Neoplasms / pathology
  • Neoplasms / therapy*
  • Patient Selection
  • Phenotype
  • Precision Medicine*
  • Predictive Value of Tests
  • Prognosis
  • Program Development
  • Research Design

Substances

  • Biomarkers, Tumor